Sign Up
OverviewAPI
BenevolentAI, a pioneer in AI-driven drug discovery, has released a shareholder letter detailing its strategic progress, collaborations, and progress in end-to-end drug discovery. The company's focus is on integrating AI and science to uncover novel biology and predict drug targets, with a lead asset in Phase 1a clinical study and emphasis on knowledge exploration tools and employee retention.

Ask a question